CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholder of the Company.25-03-2023
25-03-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholder of the Company.22-03-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Clarification sought from Caplin Point Laboratories Ltd
The Exchange has sought clarification from Caplin Point Laboratories Ltd on March 21, 2023, with reference to Movement in Volume.The reply is awaited.21-03-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholder of the Company.20-03-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholder of the Company.09-03-2023
Caplin Point subsidiary gets third USFDA approval for injections in a month
Thiamine hydrochloride Injection is generic therapeutic equivalent version of thiamine hydrochloride injection manufactured by US-based Fresenius Kabi08-03-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Thiamine Hydrochloride Injection USP08-03-2023
Caplin Steriles gets USFDA nod for Rocuronium Bromide injection
Caplin Steriles' anesthesia product will launch in US market in the coming months04-03-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Attaching herewith a Press Release regarding grant of USFDA approval for its Abbreviated New Drug Application (ANDA) Rocuronium Bromide Injection to our Subsidiary Caplin Steriles Limited. Request you to take the same on record.03-03-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that below mentioned share certificates has been reported as lost by the shareholder of the Company.01-03-2023